ArticleArchives of gynecology and obstetrics2021
Identification of potential biomarkers and metabolic pathways based on integration of metabolomic and transcriptomic data in the development of breast cancer.
Article in Archives of gynecology and obstetrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 20 citations in OpenAlex.
- METTL7A inhibits progression of colorectal cancer through the SREBP1 / FDFT1 / SQLE / CYP51A1 / cholesterol metabolic pathway.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- TMT1A inhibits lung adenocarcinoma progression by suppressing M2 macrophage polarization.iScience · 2026Article
- Hypoxanthine activates PI3K/AKT pathway and lipid metabolism, hallmarks in breast cancer metastasis.Medical oncology (Northwood, London, England) · 2025Article
- Potential prognostic and predictive biomarkers: METTL5, METTL7A, and METTL7B expression in gastrointestinal cancers.Molecular biology reports · 2025Article
- Purine salvage-associated metabolites as biomarkers for early diagnosis of esophageal squamous cell carcinoma: a diagnostic model-based study.Cell death discovery · 2024Article
- Pan-cancer analysis reveals potential immunological and prognostic roles of METTL7A in human cancers.Scientific reports · 2024Article
- RAB42 overexpression correlates with poor prognosis, immune cell infiltration and chemoresistance.Frontiers in pharmacology · 2024Article
- Nutritional Metabolomics in Diet-Breast Cancer Relations: Current Research, Challenges, and Future Directions-A Review.Biomedicines · 2023Review
- A Pilot Study on Biochemical Profile of Follicular Fluid in Breast Cancer Patients.Metabolites · 2023Article
- Conservation of rare and endangered plant species in China.iScience · 2023Review
- Evidence Based on an Integrative Analysis of Multi-Omics Data on METTL7A as a Molecular Marker in Pan-Cancer.Biomolecules · 2023Article
- Identification of Differentially Expressed Genes Related to the Lipid Metabolism of Esophageal Squamous Cell Carcinoma by Integrated Bioinformatics Analysis.Current oncology (Toronto, Ont.) · 2022Article
- Metabolomic analysis of endometrial cancer by high-resolution magic angle spinning NMR spectroscopy.Archives of gynecology and obstetrics · 2022Article
- Trident Nano-Indexing the Proteomics Table: Next-Version Clustering of Iron Carbide NPs and Protein Corona.Molecules (Basel, Switzerland) · 2022Article
- Comprehensive analysis of the significance of METTL7A gene in the prognosis of lung adenocarcinoma.Frontiers in oncology · 2022Article
- A Gene-Based Machine Learning Classifier Associated to the Colorectal Adenoma-Carcinoma Sequence.Biomedicines · 2021Article
- miR-6807-5p Inhibited the Odontogenic Differentiation of Human Dental Pulp Stem Cells Through Directly Targeting METTL7A.Frontiers in cell and developmental biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveBreast cancer (BC) is the most common type of malignant tumor and the most common cause of cancer-related mortality among women. Metabolic reprogramming is considered a hallmark of cancer, and the study of BC metabolism may be the key to the development of new strategies for diagnosis and treatment. In this study, we aimed to explore the potential metabolites and gene biomarkers for BC through the integration of metabolomics and transcriptomic data, which could further understand BC tumor biology.
methodsTranscriptome dataset GSE139038 was downloaded to explore the differentially expressed genes (DEGs) between BC and normal control (NC) samples. Metabolomics dataset MTBLS326 was downloaded and preprocessed to obtain altered metabolites. Then, the principal component analysis (PCA) and linear models were used to reveal DEGs-metabolites relations. Finally, the pathway enrichment analysis of altered metabolites was performed.
resultsA total of 280 DEGs and eight metabolites were explored between BC and NC samples. The liner module analysis investigated 28 DEGs-metabolites interactions including WASP family member 3 (WASF3)-lactate, ras-related protein Rab-7B (RAB7B)-lactate, and methyltransferase-like 7A (METTL7A)-pyruvate. Finally, pathways analysis showed that these metabolites (such as lactate and pyruvate) were mainly enriched in pathways like disorders of the Krebs cycle.
conclusionsCombining with the transcriptomic and metabolomics data, we found that lactate, pyruvate, WASF3, RAB7B, and METTL7A might be used as novel biomarkers and potential therapeutic targets for BC. In addition, the disorders of the Krebs cycle pathway might affect the progression of BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.